Monkeypox Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Prophylactic, Vaccines, Therapeutics, Tecovirimat, Brincidofovir, and Cidofovir), By Route of Administration (Oral and Injectable) By Application (Medical Imaging, Nuclear Medicine, Radioprotection, Oil Exploration, Process Industry, Life Sciences, and Others) By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others), and Region 

Monkeypox treatment market size was valued at US$ 86.4 million in 2023 which is expected to grow at a CAGR of 18.2% from 2024-2030. Two outbursts of an ailment similar to pox in gatherings of monkeys kept for research helped in the discovery of monkeypox in 1958. The monkeypox virus is the cause of monkeypox disease. Monkeypox is a type of Zoonotic disease, which is transferred from animals to humans. The virus that sources monkeypox and smallpox both come from the same virus family. However, when compared to smallpox, monkeypox is less severe. The symptoms of monkeypox are the same as smallpox but they are mild and usually non-lethal.

The rising prevalence of monkeypox caused by the monkeypox virus can lead to the market growth. Moreover, the increase in numerous dermatology diseases for example eczema and chronic disorders which consequences in weak immunity with higher probabilities of getting infested with the monkeypox virus, and growth in research and development for monkeypox treatment because of increasing demand for the cure are some primary factors that can boost the global market. Apart from these, the coronavirus pandemic has reduced the immunity of most people who are easily prone to monkeypox which can also accelerate the market in the future. However, some factors such as the rising side effects associated with drugs such as dysphoria, mild upset stomach, decreased concentration, and dry mouth can restrain the growth of the market. The absence of awareness about the monkeypox disease and lack of information about helpful treatment, as well as the sluggish sanction of certain beneficial treatments for monkeypox can hinder the market growth. Rising demand for monkeypox treatment and an increase in research and development activities for specific monkeypox treatments can create an opportunity for the global market growth.

Monkeypox Treatment Market Key Developments

• In July 2022, the U.S. Department of Health and Human Services (HHS) signed an agreement with Bavarian Nordic for 2.5 million doses of the Jynneos vaccine for the fast accessibility of the vaccines in the U.S.
• In July 2022, Bavarian Nordic received European approval for extending the vaccine label including monkeypox.
• On May 25, 2022, Roche and its subsidiary TIB Molbiol developed three unique PCR kits to detect the monkeypox virus. First LightMix Modular Virus (qPCR) kit will detect all monkeypox viruses from both West African and Central African forms of the virus. The second kit specifically detects only the West African and Central African forms of the virus. The third kit detects the orthopoxviruses and provides information about the monkeypox virus. LightCycler® 480 II Instrument or Cobas z 480 Analyzer analyzes the LightMix Modular Virus (qPCR) kits.